Teleflex Announces 200,000 Patients Treated with UroLift System for Enlarged Prostate

Minimally Invasive, Same-Day Outpatient Procedure Provides Rapid Symptom Relief and Recovery

Teleflex Announces Positive Data Emphasizing the Effectiveness of the UroLift® System Treatment for Enlarged Prostate Across Broad Patient Populations

Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World Setting

Teleflex Announces Publication of Early Patient Experience Data Highlighting the UroLift® System as a Superior Treatment to Rezum™ Steam Injection in Patients with Enlarged Prostate

Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities Quickly

In Honor of Men’s Health Month, Teleflex Announces Virtual Community Health Talk for Men with Benign Prostatic Hyperplasia

Free, Online Presentation to Address Symptoms of Enlarged Prostate, Treatment Options and Tips for Managing Condition During Pandemic

WAYNE, PA.— June 8, 2020—Teleflex Incorporated (NYSE: TFX) today announced that the company will host a free community health talk to discuss the symptoms, diagnosis and treatment options for enlarged prostate, also known as Benign Prostatic Hyperplasia (BPH). Dr. Wayne Kuang* will lead the webinar which can be viewed live on Wednesday, June 17 at 8:00 a.m. PDT and again at 4:30 p.m. PDT. Men and / or their partners from anywhere in the U.S. can attend the event.

BPH is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep and decreased quality of life.1 If left untreated, the condition can worsen over time and cause permanent bladder damage.2

“We are excited to offer our first ever virtual community health talk – a result of our efforts to stay connected with our patient community during the current pandemic,” said Dave Amerson, president of Teleflex Interventional Urology business unit. “Maintaining health is top of mind for many of us as we continue to navigate life in the midst of a pandemic. Our aim is to share information about BPH to a broad audience so that men who may be suffering from symptoms have accurate and reliable information they need to make informed decisions for their health.”

“As providers, we are dedicated to empowering our patients to get the information they need to make informed decisions about their health during this unprecedented time,” said Dr. Wayne Kuang, MD For Men, Albuquerque, NM. “Our goal for this timely webinar during Men’s Health Month is to provide attendees with a better understanding of how to address the challenges of an enlarged prostate – a condition that affects more than 40 million men in the U.S. alone3,4– and provide information about treatment solutions, such as the UroLift® System, for those experiencing BPH symptoms.”

Register to participate in this informative webinar by following this link: www.UroLift.com/seminar.

About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function.**3,4 Patients also experienced significant improvement in quality of life. Over 175,000 men have been treated with the UroLift System worldwide.*** Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in many markets worldwide. Learn more at www.UroLift.com.

About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving sexual function.**4,5 Learn more at www.NeoTract.com.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

Teleflex Announces Positive Data Showing that the UroLift® System Effectively Relieves Enlarged Prostate Symptoms While Preserving Patients’ Sexual Function*

Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged Prostate

Teleflex Celebrates 175,000 Patients Treated with the UroLift® System

Minimally Invasive Treatment for Enlarged Prostate Provides Rapid Relief1 and Durable Results2

WAYNE, Pa.— March 11, 2020—Teleflex Incorporated (NYSE: TFX) today announced that 175,000 patients have now been treated globally* with its minimally invasive UroLift® System—a safe and effective treatment for Benign Prostatic Hyperplasia (BPH) that provides rapid symptom relief and improved quality of life, while preserving sexual function.**1,3

BPH, also known as enlarged prostate, is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms, such as getting up frequently at night to urinate, that can lead to loss of productivity, depression, and decreased quality of life.4 BPH affects over 40 million men in the United States alone.5 If left untreated, the condition can worsen over time and cause permanent bladder damage.6

Teleflex Announces FDA Clearance for Expanded Indication of the UroLift® System for Treatment of Larger Prostates, Up to 100cc

Minimally Invasive Procedure Now Available to Hundreds of Thousands More Men with Enlarged Prostate, Providing Safe and Effective Symptom Relief.

Teleflex Announces Urology Times Article Highlighting the UroLift System as Providing a Superior Patient Experience for Treating Enlarged Prostate

Minimally Invasive Treatment Options for BPH Remain Critical Due to Shortcomings of Surgery and Medication

Teleflex Announces Publication of a Large Real-World Study Confirming Results from Controlled Clinical Studies of the UroLift® System

Results from Multi-Center Study Support the Application of Minimally Invasive Treatment for Broader BPH Population

Teleflex Announces Expanded Nationwide Coverage for the UroLift System for Patients with Enlarged Prostate

Coverage Decision by Anthem Increases Access to Minimally Invasive Treatment, Offering Patients Rapid, Durable Symptom Relief

Teleflex Announces Positive Results from Five Studies Underscoring the Effectiveness and Versatility of the UroLift® System Treatment for BPH

Real-World Data Presented at American Urological Association Meeting Highlight Consistency with Controlled Studies and Effectiveness in Diverse Patient Populations

Teleflex Announces Multiple Data Presentations from Studies of the UroLift® System Treatment for Enlarged Prostate at the American Urological Association 2019 Meeting

Data featuring real-world findings in a large, multi-center study, and effectiveness and sexual function preservation in diverse patient populations to be presented at the Annual Meeting of the American Urological Association

Teleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift® System to Treat Patients with Enlarged Prostate

Findings Presented at European Association of Urology Show Consistent Positive Results for Minimally Invasive UroLift System Treatment  

NeoTract Announces 100,000 Patients Treated for Enlarged Prostate with UroLift® System

Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life, While Preserving Sexual Function*1,2

NeoTract Announces Expanded Coverage for UroLift System Treatment for Patients with Enlarged Prostate

Favorable Coverage Decisions Broaden Access to This Minimally Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms

Data Suggest That Men Should Resolve to Address Their BPH Symptoms in 2019

NeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage or of Treatment Options

12-Month Results from Study of NeoTract’s UroLift® System for BPH in Men with an Obstructive Median Lobe Published in Prostate Cancer and Prostatic Diseases

PLEASANTON, Calif. – December 14, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the publication of 12-month data from the multi-center prospective MedLift™ Study of the UroLift® System treatment for Benign Prostatic Hyperplasia (BPH) in patients with an obstructive median lobe. Results were published in Prostate Cancer and Prostatic Diseases, a Nature Publishing Group journal.

NeoTract Announces Japanese Regulatory Approval for UroLift® System for Treatment of Enlarged Prostate

PLEASANTON, Calif. – November 5, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the Company has received Shonin approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the UroLift® System for the treatment of benign prostatic hyperplasia (BPH).

NeoTract Receives Phoenix 2018 Emerging Growth Company Award for Outstanding Industry Achievement

PLEASANTON, Calif. – October 29, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the company received the Phoenix 2018 Emerging Growth Company Award at the 25th Annual Phoenix Medical Device and Diagnostic Conference in Laguna Beach, Calif. sponsored by the firm Wilson Sonsini Goodrich & Rosati.

NeoTract Announces Data from New Real-World Study Demonstrating Excellent Results for UroLift® System Treatment for Enlarged Prostate

PLEASANTON, Calif. – Oct. 15, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association (AUA) in Toronto, Ontario, from a study of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

NeoTract Announces Results from Five Real-World Studies Reaffirming Efficacy and Safety of UroLift® System Treatment for Enlarged Prostate

PLEASANTON, Calif. – Sept. 24, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from five studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

NeoTract Announces Multiple Data Presentations from Studies of UroLift® System Treatment for Enlarged Prostate at the World Congress of Endourology

PLEASANTON, Calif. – Sept. 17, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that new clinical data from numerous studies of the UroLift® System for patients with benign prostatic hyperplasia (BPH) will be presented at the 36th World Congress of Endourology (WCE) 2018 Annual Conference taking place September 20-23 in Paris.

NeoTract Announces Independent Analysis in UK Confirming Cost Effectiveness of UroLift® System Treatment for Benign Prostatic Hyperplasia (BPH)

WAYNE, PA – June 08, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and patient outcomes of the UroLift System compared to transurethral resection of the prostate (TURP). The study demonstrated that replacing the current standard of care for men suffering symptoms of benign prostatic hyperplasia (BPH) with the UroLift® System could save the National Health System approximately (NHS) £27 million in costs associated with post-surgical complications.

NeoTract Announces American Urological Association (AUA) Recommendation of UroLift® System as a Standard of Care Option for the Treatment of Enlarged Prostate

PLEASANTON, Calif. – May 18, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the field of urology, today announced that the American Urological Association (AUA) has recommended the use of the UroLift® System as a standard of care treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

NeoTract To Unveil New Clinical Data on the UroLift® System at American Urological Association 2018 Meeting

PLEASANTON, Calif. - May 16, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced a series of presentations planned for the 113th Annual Meeting of the American Urological Association (AUA) taking place May 18 - 21 in San Francisco.

NeoTract Announces Data from Large Real-World Study of UroLift® System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate

PLEASANTON, Calif. – March 19, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the field of urology, today announced the results from the first analysis of a retrospective registry of more than 800 UroLift® System procedures performed at seven centers in North America, Europe and Australia.

Teleflex Incorporated Completes Acquisition of Neotract

Teleflex

Contact:
Jake Elguicze
Treasurer and Vice President of Investor Relations
610-948-2836

Teleflex Incorporated to Acquire NeoTract

FOR IMMEDIATE RELEASE September 5, 2017

NeoTract Inc. Announces Cigna Coverage for the UroLift® System for Enlarged Prostate

PLEASANTON, Calif.– May 11, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that Cigna, a global health service company that provides insurance for over 14 million Americans, has established coverage for the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

NeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift® System at American Urological Association 2017 Meeting

PLEASANTON, Calif.– May 8, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced activities planned for the 112th American Urological Association Annual Meeting taking place May 12-16 at the Boston Convention and Exhibition Center in Boston, Mass.

NeoTract Inc. Receives #Gamechanger Award for Innovation

PLEASANTON, Calif.– April 13, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company has been recognized with the Innovation Tri-Valley Leadership Group’s #Gamechanger Award.

NeoTract’s Minimally Invasive UroLift® System for Enlarged Prostate Now Shown to be Durable Through Five Years: Results from Pivotal L.I.F.T. Randomized Study Presented

PLEASANTON, Calif. and LONDON – March 27, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced five-year follow-up data from the pivotal, randomized L.I.F.T. IDE study, which evaluated the safety and effectiveness of the company’s novel UroLift® System in patients with symptomatic benign prostatic hyperplasia (BPH).

Revolutionary UroLift® System Launches in Ireland

PLEASANTON, CA, US March 23, 2017 - NeoTract, Inc., announced today that the largest private health insurer in Ireland, Vhi Group, is to reimburse the minimally invasive UroLift System in the country - making a day case surgical treatment requiring no cutting, heating or removal of tissue available for the first time to thousands of Irish men with a urological condition described as very common in older males.
 
The UroLift System treats symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men. Delivered during a minimally-invasive procedure, the UroLift implants act like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients typically recover from the procedure quickly, and often return to their normal routines with minimal downtime.

NeoTract’s UroLift® System Featured in the American Urological Association’s Urology Residents BPH/LUTS Training Program

PLEASANTON, Calif. – March 21, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company’s UroLift System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH), was featured in an American Urological Association (AUA) training event that took place last week at the AUA headquarters in Linthicum, Md. 

NeoTract Convenes Leading Urologists for Summit on Treating Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, recently hosted more than 60 urologists from around the country to review clinical data and share best practices for using the UroLift® System to improve the care of patients with enlarged prostate, or benign prostatic hyperplasia (BPH). Highlights from the meeting included robust data presentations and the designation of three new UroLift Centers of Excellence from Jamestown, New York; Pittsburgh, Penn., and Fullerton, Calif.

NeoTract Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif. – NeoTract, Inc., a medical device company that markets the UroLift System for treating enlarged prostate, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference. Dave Amerson, President and CEO of NeoTract, is scheduled to present on Monday, January 9th at 1:30pm PT at the Westin St. Francis in San Francisco, CA.

NeoTract’s UroLift System Featured in Five Presentations at World Congress of Endourology Meeting in South Africa

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced presentations at the 34th World Congress of Endourology (WCE) in Cape Town, South Africa, featuring the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

NeoTract, Inc. Announces Medicare Administrative Contractor First Coast Service Options (FCSO) Coverage for the UroLift® System for BPH

PLEASANTON, Calif. –  NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that First Coast Service Options, Inc., the Medicare Administrative Contractor (MAC) covering Florida, Puerto Rico and the U.S. Virgin Islands, has established coverage for the UroLift® System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

UK Government names UroLift® System to be fast track funded for the NHS as a strategically important product to improve UK healthcare

LONDON –The UroLift System treatment for enlarged prostate has been highlighted as a strategically important product for the future of the NHS, as one of a handful of disruptive healthcare technologies that can improve the UK’s public healthcare system, in a new report and funding mechanism for innovations by the UK Government.

NeoTract Announces Launch of UroLift Center of Excellence Program Recognizing Urologists Dedicated to Optimal Treatment Experience

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in urology, today announced the launch of UroLift® Center of Excellence program to spotlight urologists dedicated to optimizing the treatment experience for patients treated with the company’s UroLift System.

UroLift was featured on The Doctors!

 

NeoTract’s Innovative UroLift System To Treat Enlarged Prostate Appears on “The Doctors” National Television Show

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in urology, announced that the company’s UroLift® System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), has appeared on the popular television program “The Doctors,” distributed nationally by CBS.

NeoTract Receives Phoenix 2016 Most Promising New Product Award for UroLift® Device for Enlarged Prostate

NeoTract, Inc., a medical device company focused on addressing unmet needs in urology, today announced that the company’s UroLift® System received the Phoenix 2016 Most Promising New Product Award at the 23rd Annual Phoenix Conference in Laguna Beach, Calif. The UroLift System was recognized for its novel and much less invasive approach for alleviating symptoms caused by benign prostatic hyperplasia (BPH), also known as an enlarged prostate.

NeoTract, Inc. Announces Positive Coverage Decisions from Geisinger Health Plan and Emblem Health for UroLift® Implant Procedure

NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced new positive coverage decisions from Geisinger Health Plan and Emblem Health, expanding access to the UroLift® System for the treatment of their members with benign prostatic hyperplasia (BPH).

NeoTract, Inc. Announces Publication of Data Showing Excellent Long-Term Durability of UroLift® Treatment

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced the peer-reviewed publication of four-year follow-up data from the pivotal, randomized L.I.F.T. IDE study, which evaluated the safety and effectiveness of the company’s novel UroLift® System in patients with symptomatic benign prostatic hyperplasia (BPH), in Urologic Clinics of North America.

NeoTract Announces UroLift System Now Available to Millions More Americans

PLEASANTON, Calif. – July 7, 2016 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced the recent addition of several new insurance positive coverage decisions to expand access to the UroLift® System as a covered benefit for many more men across the United States, including Medicare, Medicaid and commercial insurance beneficiaries.

NeoTract Announces Sponsorship of Third Annual Drive for Men’s Health

PLEASANTON, Calif. – June 14, 2016 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced its sponsorship of the third annual “Drive for Men’s Health” event and presentation by urologist Dr. Carson Wong, chief of urology for University Hospitals Ahuja Medical Center, at the event’s stop at Anytime Fitness today in Cleveland, Ohio.

NeoTract, Inc. Announces Data Showing Excellent Durability of Results for UroLift System at Four Years

 

The European Association of Urology upgrades UroLift® System trial data to its highest possible classification - Level 1A - in its Guidelines 

MUNICH, GERMANY – March 14, 2016 – The UroLift® System treatment for enlarged prostate was showcased today at the European Association of Urology international conference with the presentation of the four-year durability results of the multi-national L.I.F.T. randomised study and the two year results of the multi-national BPH6 randomised study.  These promising results were presented as the EAU Guidelines for male lower urinary tract symptoms (LUTS) upgraded the rating for UroLift data to the highest possible classification, Level 1A.  The EAU guidelines update comes as NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announces key gains in European government healthcare system reimbursement in multiple markets.

NeoTract, Inc. Announces First Patients Enrolled in New Study to Expand UroLift System Indication

PLEASANTON, Calif. -- NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that the first patients have been enrolled in the MedLift™ U.S. IDE trial.

The Sexual Side Effects of BPH Therapy: Experts Discussion

Journal of Sexual Medicine Supplement: 

The “Other” Prostate Condition: Benign Prostatic Hyperplasia Affects Millions of U.S. Men, Can Severely Impact Quality of Life

PLEASANTON, Calif. and Washington, D.C.  – Lack of awareness about a common health condition may be causing millions of men to suffer unnecessarily. Benign prostatic hyperplasia (BPH), also known as enlarged prostate, affects more than 37 million men in the United States alone. Unfortunately, many men postpone treatment for this disorder because of concerns about side effects; however, their concerns may be alleviated with additional information.

NICE Evaluation and Tariff Code Announcements to Increase UroLift® System Availability in UK NHS Patients with Enlarged Prostate

PLEASANTON, CA, US - NeoTract, Inc., today welcomed the announcement by NICE that its UroLift® System (Prostatic Urethral Lift) to treat an enlarged prostate (benign prostatic hyperplasia) saves the National Health Service (NHS) up to £286 ($443) per patient as a day case, compared to the most commonly used surgical intervention. NICE acknowledged the UroLift System has unique benefits, including preservation of sexual function, improved quality of life, reduced recovery time and the ability to treat high risk patients.

NeoTract, Inc. Announces Successful Live Case Transmission at AUA 2015

PLEASANTON, Calif. and NEW ORLEANS, La. –  NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced a successful live case using the UroLift® System to treat a patient with Benign Prostatic Hyperplasia (BPH) during the American Urological Association's 2015 Annual Meeting in New Orleans, La., to an audience of more than 1,500 attendees.

NeoTract, Inc. Announces Excellent Data From Two Studies of the Minimally Invasive UroLift System Treatment for Enlarged Prostate

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the American Urological Association's 2015 Annual Meeting from two studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH). 

NeoTract Announces Positive Guidelines from European Association of Urology for Minimally Invasive Treatment for Benign Prostatic Hyperplasia

PLEASANTON, Calif. –  NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that the European Association of Urology (EAU) has given the UroLift® System a positive recommendation for the treatment of patients with benign prostatic hyperplasia (BPH) in its newly updated “Guidelines for the Management of NonNeurogenic Male Lower Urinary Tract Symptoms, Including Benign Prostatic Obstruction,” published in European Urology.

NeoTract, Inc. Receives Edison Award for Innovative Treatment for Men with Enlarged Prostate

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today the company has received a Bronze Edison Award for the company’s UroLift® System, a novel minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), also called enlarged prostate. Awards were presented during a gala event last night at Capitale in New York City. 

NeoTract Receives Reimbursement Coverage from Noridian Healthcare Solutions for Minimally Invasive Treatment for Enlarged Prostate

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that Medicare Administrative contractor Noridian Healthcare Solutions, LLC has approved coverage for the company's UroLift® System for the treatment of benign prostatic hyperplasia (BPH).

NeoTract, Inc. Announces Publication Showing Sustained Safety and Efficacy Benefits for the Minimally Invasive UroLift® System Treatment for Enlarged Prostate

PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced publication of two-year results from the 206-patient L.I.F.T. IDE Study, a multi-center, randomized, blinded study of the novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

NeoTract, Inc. Announces CMS Reimbursement for Innovative Minimally Invasive Procedure for Enlarged Prostate

PLEASANTON, Calif. – November 10, 2014 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the Department of Health and Human Services, through the Centers for Medicare and Medicaid Services (CMS), has approved two new Category I Current Procedure Terminology (CPT®) codes for the UroLift® System treatment for benign prostatic hyperplasia (BPH), effective January 1, 2015.

Sexual Function No Longer Inevitable When Treating Enlarged Prostate

PLEASANTON,  CA, US  --­‐ NeoTract,  Inc., today welcomes the publication of a paper in the British Journal of Urology International which calls for men suffering from enlarged prostate to discuss with their doctors the likely impact of treatment options on their sexual function.  Most procedures and many medications can cause sexual dysfunction.  Clinical studies show that treatment with the UroLift®  System has not been associated with any new onset of sustained ejaculatory or erectile dysfunction.    

Perito Urology is NeoTract’s First UroLift® System Training Center of Excellence in the U.S.

PLEASANTON, Calif. -- NeoTract, Inc., today announced that Perito Urology in Coral Gables, Florida is the company’s first National Center of Excellence for training physicians on the UroLift® System implant procedure.

NeoTract Announces Aetna US Healthcare and Coventry Health Care Positive Coverage Decision Regarding UroLift® Implant Procedure for Men with Enlarged Prostate

Clinical Policy Bulletin: Benign Prostatic Hypertrophy (BPH) Treatments

NeoTract’s UroLift® Implant Procedure for Men with Enlarged Prostate Receives Medicare and Medicaid Outpatient Billing Codes for Reimbursement

PLEASANTON, Calif. - NeoTract, Inc., today announced that the Centers for Medicare and Medicaid Services (CMS) have issued two new codes that describe the UroLift® implant procedure for the treatment of enlarged prostate in the April 2014 Update of the Hospital Outpatient Prospective Payment System (OPPS). Effective April 1, 2014, hospitals will be able to request Medicare reimbursement for the UroLift implant procedure using these newly issued specific Healthcare Common Procedure Coding System (HCPCS) codes. The UroLift System was cleared for use by the FDA on September 13, 2013.

NICE gives go ahead to NeoTract’s groundbreaking UroLift® Prostate Implant that can preserve sexual function while offering urinary symptom relief for millions of men affected by enlarged prostates

PLEASANTON, CA, US, - NeoTract, Inc., today announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued an Interventional Procedure Guidance (IPG) approving the UroLift prostatic urethral lift implant for use by UK doctors. The NICE guidance was made following consultations with independent clinical experts and a literature review.
NICE says: “The specialist advisers listed key efficacy outcomes as symptom improvement, improvement in quality of life, reducing or stopping medical therapy [drug therapy], flow improvement, reduction in residual volume and maintenance of sexual and ejaculatory function”.

UroLift® System Treatment: Expert Panel Discussion

Urology Times Supplement: 

First U.S. Patient Treated Following FDA Clearance of NeoTract’s UroLift® System

PLEASANTON, Calif. - NeoTract, Inc., today announced that the first patient in the United States has been treated with its commercial UroLift® System, the first permanent implant to treat symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. Cleared by the U.S. Food and Drug Administration on September 13, 2013, the UroLift System is designed to relieve symptoms caused by an enlarged prostate, while preserving sexual function.

NeoTract, Inc. Receives U.S. FDA De Novo Approval for the UroLift® Prostate Implant

PLEASANTON, CA, - NeoTract, Inc., today announced that it received De Novo approval from the U.S. Food and Drug Administration (FDA) to market the novel UroLift® System, the first permanent implant to relieve low or blocked urine flow in men age 50 and older with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate. The FDA’s action will provide U.S. surgeons and patients access to a treatment option that uniquely reduces urinary symptoms without chemically altering or surgically ablating, cutting or removing prostatic tissue. Data from the recent 206-patient randomized controlled L.I.F.T. study showed patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function. Patients also experienced a significant improvement in quality of life.

NeoTract’s UroLift® Prostate Implant Demonstrates Strong Safety and Efficacy Benefits with Minimally Invasive BPH Treatment

PLEASANTON, CA, - NeoTract, Inc., today announced the successful results of the 206-patient L.I.F.T. IDE Study, a multi-center, randomized, blinded study in patients with Benign Prostatic Hyperplasia (BPH). All primary and secondary endpoints were met and the study results corroborated prior published data on the novel UroLift® System treatment, a minimally invasive procedure to place permanent UroLift implants. Patients receiving the UroLift implants reported rapid symptomatic improvement, increased urinary flow rates, and preserved sexual function. A significant improvement in Quality of Life for patients was also observed.